Main Menu


Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.

Disease site: Breast cancer

Treatment modality: Interventional screening

Status: Recruitment suspended

Trial details

AURORA is a large, multinational, collaborative molecular screening programme to improve understanding of metastatic breast cancer and future treatment of this disease.

In total, 1300 women and men from 14 European countries are expected to take part. In the UK, 100 patients will be recruited over a 2 year period and will be followed up for a further 10 years. Patients with either newly diagnosed local relapse or metastatic disease, or treated with no more than one line of systemic therapy in the metastatic setting, will be approached to participate.

AURORA will collect biopsy samples from both primary and metastatic tumours for molecular profiling with a panel of more than 400 cancer related genes. Blood samples collected at baseline, every 6 months and at new disease progression will also undergo molecular screening.

Information gained from the AURORA programme will help to analyse and evaluate why some tumours respond poorly to standard treatment while others respond exceptionally well, and why breast cancer metastasises.

Further information

Chief Investigator: Professor David Cameron, University of Edinburgh and NHS Lothian

ICR-CTSU Scientific Lead: Professor Judith Bliss

UK trial management contact: [email protected]

Sponsor and funder: Breast International Group (BIG)

View AURORA on the National Institute for Health Research website: NIHR - Be Part Of Research and the BIG website.

A plain English summary is available from Cancer Research UK.

Publications and presentations

There have been no presentations or publications to date.

Clinical trials

Division of Clinical Studies

The division carries out or coordinates high-quality trials and translational research at both an early phase – typically to test new targeted drugs – and a later stage.